Table 1.

Retreatment criteria in nAMD clinical trials

Trial	Regimen	Retreatment criteria
CATT [18]	PRN	Any fluid on OCT, new/persistent haemorrhage, decreased VA vs. previous exam, leakage and/or increased lesion size on FA
IVAN [19]	Monthly vs. PRN	Any SRF or increasing IRF on OCT, new haemorrhage, VA loss ≥ 10 letters, fluorescein leakage greater than only 25% of lesion circumference or expansion of CNV on FA
GEFAL [20]	PRN	Loss of ≥ 5 letters with no obvious atrophy or subretinal fibrosis AND any fluid on OCT, active “exudation” on OCT (SRF unless stable since the last 3 monthly injections or macular edema with IRF, or increase in CRT ≥ 50 µm vs. previous exam), increased CNV area/persistent leakage on FA, new/persistent subretinal or intraretinal haemorrhage
HARBOR [21]	PRN	≥ 5-letter decrease from previous visit AND any evidence of disease activity on OCT
LUCAS [22]	T&E	Any fluid on OCT, new/persistent haemorrhage, new/persistent dye leakage, or increased lesion size on FA
VIEW [23]	PRN	Any fluid on OCT, loss of ≥ 5 letters vs. best previous score with recurrent fluid on OCT, increase in CRT ≥ 100 µm vs. lowest previous value, new-onset classic neovascularisation, new/persistent leakage on FA, new haemorrhage
TREX-AMD [24]	T&E	"Wet macula” (any unresolved IRF/SRF on OCT), subretinal/intraretinal haemorrhage related to exudative AMD
CAN-TREAT [25]	Monthly vs. T&E	The presence of any fluid on OCT, vision loss of > 5 ETDRS letters, presence of new haemorrhage or progression of choroidal neovascularisation, or a combination thereof
RIVAL [26]	T&E	Markers of disease activity: a loss of VA of ≥ 5 letters than the best VA recorded since treatment started (where VA loss is considered, by the investigator, to be due to disease activity); new retinal haemorrhage; the presence of any IRF or SRF on OCT. Dose adjustment:1 criterion present = interval reduced by 2 weeks; ≥ 2 criteria present = interval brought back to 4 weekly
ALTAIR [27]	T&E	New or persistent fluid with unchanged or increased fluid volume on OCT, vision loss of > 5 ETDRS letters, an increase in CRT of ≥ 100 μm at the central 1 mm compared with the lowest previous value measured by OCT, new-onset neovascularization based on fundus examination and multi-imaging assessment, new macular hemorrhage or new fluid or persistent intra- or subretinal fluid with unchanged or increased fluid volume from the previous visit as indicated by total OCT scan area

CNV choroidal neovascularisation, CRT central retinal thickness; ETDRS Early Treatment of Diabetic Retinopathy Scale, FA fluorescein angiography, IRF intraretinal fluid, OCT optical coherence tomography, PRN pro re nata, SRF subretinal fluid, T&E treat and extend, VA visual acuity